

1.- 11. (Canceled)

12. (Currently Amended) The composition of Claim 14, wherein said inactivated human immunodeficiency virus is an inactivated autologous human immunodeficiency virus (HIV).

13. (Canceled)

14. (Currently Amended) A composition, comprising an antigen presenting cell pulsed with an inactivated non-recombinant human immunodeficiency virus (HIV), wherein the composition expands expression of virus-specific ~~CB8+T~~ CD8+T cells.

15. (Currently Amended) The composition of Claim 14 38, wherein said virus-specific ~~CB8+T~~ CD8+T cells kill HIV-infected cells.

16.-32. (Canceled)

33. (Previously Presented) The composition of Claim 14, wherein said antigen-presenting cell is a dendritic cell.

34. (Previously Presented) The composition of Claim 33, wherein said dendritic cell is an autologous dendritic cell.

35. (Previously Presented) The composition of Claim 33, wherein the dendritic cell is a monocyte-derived dendritic cell.

36. (Previously Presented) The composition of Claim 14, wherein the inactivated human immunodeficiency virus is chemically inactivated.

37. (Previously Presented) The composition of Claim 14, wherein the inactivated human immunodeficiency virus is inactivated by 2,2'-dithiopyridine or aldrithiol-2.

38. (New) The composition of Claim 14, wherein the inactivated human immunodeficiency virus is non-thermally inactivated.

39. (New) The composition of Claim 36, wherein the inactivated human immunodeficiency virus is an autologous human immunodeficiency virus.

40. (New) The composition of Claim 38, wherein the inactivated human immunodeficiency virus is an autologous human immunodeficiency virus.